Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xilonix with Onivyde and 5-FU in advanced pancreatic cancer with cachexia
NCT03207724Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of bermekimab in pancreatic adenocarcinoma (PDAC) and cachexia. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Oct 2017; status: completed.
02
Drugs
bermekimab
03
Conditions
pancreatic adenocarcinoma (PDAC)cachexia
Beyond the preview
Go deeper on NCT03207724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207724.